Comparison · NCT01419665-77b7605e
GP2013 vs Rituximab: To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GP2013 vs Rituximab: To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period. Trial comparisons, record NCT01419665-77b7605e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01419665-77b7605e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.148 | 0.113 | 0.192 | wilson | |
| Risk in group 2 | 0.134 | 0.101 | 0.176 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0137 | -0.0412 | 0.0687 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.1 | 0.748 | 1.62 | log | |
| Odds ratio, group 1 over group 2 | 1.12 | 0.713 | 1.76 | log | |
| Number needed to treat, for one more participant with the outcome on GP2013 than on Rituximab | 72.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GP2013 | Experimental Type: Biological/Vaccine | 46 | 311 | OG000 |
| Group 2 | Rituximab | Comparator Type: Biological/Vaccine | 42 | 313 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period
- Description
- Time frame
- 24 weeks
- Population
- per protocol set, participants with measure
Source ClinicalTrials.gov
Trial
- Title
- GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)
- NCT number
- NCT01419665
- Phases
- PHASE3
- Conditions
- Follicular Lymphoma
- Interventions
- GP2013, rituximab
- Lead sponsor
- Sandoz
- Results first posted
- 2021-05-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01419665?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01419665-77b7605e